Comments from Ms. Merel Nissenberg, President of the National Alliance of State Prostate Cancer Coalitions have appeared recently in several issues of Prostatepedia.
Rivanna Health Publication's Prostatepedia features informal conversations with doctors, patients, and activists about prostate cancer each month tackling a different topic facing prostate cancer patients today.
Here are links to these recent articles:
Helping Patients Navigate the World of Clinical Trials
In this May 2019 article, Ms. Nissenberg, along with Mr. Tom Kirk, who is the Vice-President of the California Prostate Cancer Coalition, discuss "how, why and when patients should consider a clinical trial.
Merel Nissenberg: Focal Therapy on Prostate
In this April 2019 article, Ms. Nissenberg discusses the use of Focal Therapy as a treatment for Prostate Cancer. Interest in focal therapy is fueled by the promise of cancer control with fewer side effects than are seen after radiation or radical prostatectomy.
Merel Nissenberg On Non-Metastatic Castrate-Resistant Prostate Cancer
In thie article, Ms. Nissenberg discussed non-metastatic, castrate-resistant prostate cancer (nmCRPC), a clinical state in which a patient on androgen-deprivation therapy (ADT) has a rising PSA but there are no radiological findings of metastases on CT or bone scan.
Ms. Merel Nissenberg: Hypofractionated Radiotherapy
Ms. Merel Nissenberg is the President of the National Alliance of State Prostate Cancer Coalitions, a nation-wide organization comprised of state prostate cancer coalitions dedicated to saving men’s lives and enhancing the quality of life of prostate cancer patients and their families through awareness, education, and the development of a public policy network. In this article she offers two views of hypofractionated radiotherapy for prostate cancer.
Genetics Testing + Counseling
In the article, Ms. Nissenberg notes the National Alliance of State Prostate Cancer Coalitions strongly endorses the use of genetic testing and genetic counseling for prostate cancer, and urges clinicians to read, consider, and follow the scientifically sound suggestions of the 2017 Philadelphia Prostate Cancer Consensus Statement on the Role of Inherited Prostate Cancer Risk.
Proceeding from the 13th Annual Meeting of NASPCC